The DETOUR 2 study is a prospective, single-arm, international, multi-center clinical evaluation of the novel DETOURTM System for fully percutaneous femoropopliteal bypass procedures. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced the 24-month results […]

IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies for the interventional treatment of vascular disease, announced the 12-month results of the DETOUR 2 trial during a late-breaking clinical trial session at the 2022 VIVA Vascular InterVentional Advances (VIVA) […]

The DETOUR 2 study is a prospective, single-arm, international, multi-center clinical evaluation of the novel DETOUR™ System for fully percutaneous femoropopliteal bypass procedures. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives with innovative interventional treatments for vascular disease, recently announced the 12-month […]